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ABSTRACT
Introduction As countries approach the UNAIDS 
95-95-95 targets, there is a need for innovative and 
cost- saving HIV testing approaches that can increase 
testing coverage in hard- to- reach populations. The 
HIV Self- Testing Africa- Initiative distributed HIV self- 
test (HIVST) kits using unincentivised HIV testing 
counsellors across 31 public facilities in Malawi, South 
Africa, Zambia and Zimbabwe. HIVST was distributed 
either through secondary (partner’s use) distribution 
alone or primary (own use) and secondary distribution 
approaches.
Methods We evaluated the costs of adding HIVST to 
existing HIV testing from the providers’ perspective in 
the 31 public health facilities across the four countries 
between 2018 and 2019. We combined expenditure 
analysis and bottom- up costing approaches. We also 
carried out time- and- motion studies on the counsellors 
to estimate the human resource costs of introducing 
and demonstrating how to use HIVST for primary and 
secondary use.
Results A total of 41 720 kits were distributed during 
the analysis period, ranging from 1254 in Zimbabwe to 
27 678 in Zambia. The cost per kit distributed through 
the primary distribution approach was $4.27 in Zambia 
and $9.24 in Zimbabwe. The cost per kit distributed 
through the secondary distribution approach ranged 
from $6.46 in Zambia to $13.42 in South Africa, with 
a wider variation in the average cost at facility- level. 
From the time- and- motion observations, the counsellors 
spent between 20% and 44% of the observed workday 
on HIVST. Overall, personnel and test kit costs were the 
main cost drivers.
Conclusion The average costs of distributing HIVST 
kits were comparable across the four countries in our 
analysis despite wide cost variability within countries. 
We recommend context- specific exploration of potential 
efficiency gains from these facility- level cost variations 
and demand creation activities to ensure continued 
affordability at scale.
BACKGROUND
UNAIDS set the 95-95-95 targets with the first 
95 aiming for 95% of people living with HIV 
(PLHIV) being aware of their status by 2030.1 
These fast- track targets have contributed to 
unprecedented progress towards ending the 
Key questions
What is already known?
 ► HIV self- testing has been proven to be acceptableand 
effective at reaching populations left behind bycon-
ventional testing approaches. Community- baseddoor- 
to- door distribution of HIV self- testing has effectively 
reached men and first- time testers. Thereare econo-
mies of scale to the community- based distribution of 
HIV self- testing with personnel costs asan important 
cost driver.
What are the new findings?
 ► We evaluated the costs of integrating HIV self- testing 
to existing testing services in public health facilities 
across four Southern African countries. We found 
that costs of integrating HIV self- testing in the public 
health facilities ranged from US$4.27- US$13.42 per 
kit distributed. Personnel and cost of test kits were im-
portant cost drivers. Time- and- motion studies showed 
that non- compensated healthcare workers spent be-
tween 20-44% of the observed workday on direct and 
indirect HIV self- testing activities. There are existing 
facility- level economies of scale and efficiency gains 
from integrating HIV self- testing to existing testing 
services.
What do the new findings imply?
 ► Our results inform resource needs for implementers 
seeking to integrate HIV self- testing to existing testing 
services. We bring awareness to the staff time com-
mitments required by such facility- based integrated 
services. We additionally emphasize on the need for 
context when deciding how and extent of integration
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AIDS epidemic, especially in Eastern and Southern Africa, 
the region most affected by the epidemic.2
Despite this progress, the region still faces challenges in 
reaching men and key populations with testing.2 Some of 
the hindrances to accessing testing include lack of conve-
nient and accessible testing options especially for rural 
communities, high indirect user costs in accessing testing 
and privacy concerns associated with their test results.3–6
HIV self- testing (HIVST), which is the process 
whereby a person collects their specimen, performs 
an HIV test and interprets their own results in private, 
can increase the number of PLHIV who are aware of 
their status and initiate treatment.7 HIVST provides 
an opportunity for discretion and convenience when 
testing and is highly acceptable among young people, 
adult men and first- time testers.3 7 8
We explore the costs of integrating HIVST into 
existing HIV testing services in public primary 
health facilities in Malawi, South Africa, Zambia and 
Zimbabwe between 2018 and 2019. Service integra-
tion involves joining together different services to 
maximise technical efficiency through economies 
of scale and scope, allocative efficiency and health 
outcomes.9 10 Previous work on integration of HIVST 
into outpatient services in Malawi reported an 
increase in outpatient testing when compared with 
standard of care (SoC).11
To our knowledge, this is the first multicountry 
cost analysis of the integration of HIVST into public 
health facilities. Such information is essential to 
designing sustainable and cost- effective models of 
HIVST as countries approach the UNAIDS 95-95-95 
targets. Previous studies reporting costs of distrib-
uting HIVST in the region were either on a small 
scale12 or focused on the community- based distribu-
tion of HIVST.5 13 14 These studies reported average 
full costs (cost per kit distributed) in 2019 US dollars 
of $9.66 and $8.91 for Malawi, $17.70 for Zambia and 
$14.91 for Zimbabwe5 13 and average incremental 
costs of $15.40 and $14.00 in early and later phases of 
a community- based distribution of HIVST in Lesotho, 
respectively.14 The only other cost analysis of HIVST 
integration into facility- based testing services was 




HIVST distribution was done by unincentivised Depart-
ment/Ministry of Health staff (HIV testing counsellors) 
supported by Population Services International (PSI) 
in Malawi and Zimbabwe, Society for Family Health 
in Zambia and the Wits Reproductive Health and HIV 
Institute in South Africa. Unitaid funded the supporting 
partners and commodities under the Self- Testing Africa 
(STAR) Initiative. Primary and secondary distribution 
approaches for HIVST were implemented. Primary distri-
bution of HIVST involved collecting a test kit for one’s use 
on- site, while secondary distribution involved collecting a 
test kit for use by sexual partners off- site. Table 1 provides 
a summary of the distribution approaches by country.
Integration was from the first point of encounter with 
the facilities’ waiting area where clients were briefed on 
HIVST as they waited for their consultations. Willing 
clients would visit the HIV testing services (HTS) room 
and opt for either a provider- administered finger prick 
test or provider- assisted oral- fluid based HIVST (which 
could be immediately confirmed by a facility- based 
provider in the event of a reactive result). In the secondary 
distribution channel, willing pregnant women attending 
antenatal care, where the HIVST kit was offered for the 
partner at their first visit or HIV positive clients (newly 
diagnosed or enrolled in the ART programme), were 
offered kits for use by their sexual partners. The sexual 
partners were encouraged through the recipient of the 
HIVST kit to visit the facility for a confirmatory test if they 
screened positive. Online supplemental figure A1- A4 in 
the appendix give more detailed information on the inte-
gration process in each country.
South Africa’s HIVST kit distribution and cost analysis 
was carried out across eight facilities in Gauteng and North 
West Provinces. In Zambia, distribution and cost analysis 
took place in two facilities in Lusaka district, while in 
Zimbabwe, costing was carried out for distribution in two 
large facilities in Mashonaland East. The Zimbabwe facil-
ities were purposively sampled based on their proximity 
to Harare, which is where the country’s PSI headquar-
ters was located. Malawi’s distribution was implemented 
as a three- arm pragmatic cluster randomised trial in 27 
facilitiess in the Southern region.16 The arms comprised 
SoC, HIVST- only and HIVST plus financial incentive 
(HIVST+FI). SoC arm offered the ANC and index clients 
Table 1 Integrated distribution of HIV self- tests into routine HIV testing services by country
Country Channel Model Target population
Malawi and South 
Africa
Secondary distribution only Antenatal care distribution.
Index distribution.
Sexual partners of pregnant women.
Sexual partners of HIV positive clients (newly 
identified or on antiretroviral therapy).





Sexual partners of pregnant women.
Sexual partners of HIV positive clients (newly 
identified or on antiretroviral therapy).
Clients attending facility outpatient services.
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letters inviting their partners to the facility for an HIV test. 
The HIVST- only and the HIVST+FI arms offered HIVST 
in addition to the invitation letters. In the HIVST- only 
arm, partners were encouraged to come to the facility 
only if they had screened positive. In the HIVST+FI arm, 
partners were encouraged to come to the facility regard-
less of their screening result and were given a US$10 
incentive as reimbursement for their time plus transport. 
We analysed the costs of all three arms.
Patient and public involvement
Patients and/or the public were not involved in the 
design, recruitment, conduct, reporting or dissemination 
plans of this research.
Cost analysis
Economic costs of HIVST integration were estimated 
from the providers’ perspective, with data collected 
between 2018 and 2019 and reported in 2019 US dollars. 
We converted local currencies to their US$ equivalent 
based on each country’s average exchange rate for 2019 
as sourced from the respective countries’ Reserve Bank 
websites.17–19 The costing process involved a combination 
of expenditure analysis in estimating financial costs and 
a bottom- up costing to identify and value any additional 
or donated items not included in expenditure records. 
We focused on HIVST costs alone because the HTS costs 
in this setting have been extensively studied and reported 
elsewhere.15 20
The expenditure analysis was used to track actual imple-
mentation expenses such as cost of buying the test kits 
and other supplies, salaries, transportation and storage. 
The bottom- up costing was used to identify and value 
donated items at the facility- level such as equipment and 
space. At the facility- level, we only included economic 
costs directly related to HIVST distribution such as the 
counsellors’ time, facility space and equipment, and 
excluded indirect costs such as overheads (utilities and 
facility security).
The costs were categorised into capital and recurrent. 
Capital costs included project start- up costs, training, 
sensitisation and equipment. Recurrent costs included 
operational costs such as personnel and per diems, 
supplies and cost of test kits, among other costs. Capital 
costs were annualised over the life course of the project, 
that is, 2 years. We used a discount rate of 3% as recom-
mended in literature and to facilitate comparison with 
our earlier work in the same countries.13 14 20 21 We varied 
this discount rate between 0% and 15% to reflect the 
range in official rates across the countries.
The implementing partners introduced multiple 
models of distributing HIVST in addition to the facility 
integrated model. Shared costs between models were allo-
cated based on the assumptions presented in appendix 
online supplemental table A1. The allocation factors 
for shared costs included the proportion of distributors 
trained, kits distributed, direct expenditure and vehicle 
mileage by model, among other variables.
we used a combination of methods to allocate the 
time of facility staff involved in other activities alongside 
HIVST distribution, . In all countries except Zambia, we 
undertook time- and- motion studies to estimate provider 
time for the HIVST process. We could not conduct time- 
and- motion studies in Zambia due to delays in obtaining 
ethics clearance within the project implementation phase. 
There, we retrospectively interviewed the counsellors 
to understand the proportion of time allocated to HIV 
testing and HIVST services. We asked the counsellors to 
estimate the percentage of time allocated to HIV testing 
services and of this, the percentage allocated to HIVST 
services. We converted these proportions to equivalent 
overall HIV testing and HIVST time in minutes based on 
the counsellors stated working hours.
In South Africa, the initial ethics approval provided for 
up to 3 hours of continuous observations of the counsel-
lors; this was later revised to continuous observation of 
a full working day after ethics amendments. More than 
half of the observations included in this analysis were 
conducted during the 3- hour observation phase.
We obtained the counsellors’ salaries from the facilities 
and multiplied by the average time obtained from the 
time- and- motion studies and interviews to estimate the 
facility- level personnel cost of HIVST. Overall personnel 
costs are a combination of the facility- level personnel cost 
and personnel costs at the PSI, Society for Family Health 
and the Wits Reproductive Health and HIV Institute 
central- level offices.
Data collection tools were developed as part of a 
collaborative process under the STAR- Initiative consor-
tium and standardised across the countries except for 
Zambia (for the time- and- motion tool only) where we 
could not conduct time- and- motion studies. The obser-
vations involved timing and recording on paper forms 
the counsellors’ activities throughout their working day. 
We used the same tools across all HIVST distribution 
models including the integrated facility- based distribu-
tion. Table 2 presents the activities and their description. 
The activities were broadly categorised into direct and 
non- direct patient services, with direct patient services 
capturing time spent in contact with patients. The direct 
patient services time was allocated directly to either 
HIVST or finger prick testing. The non- direct patient 
services time was allocated to HIVST or finger prick 
testing using direct HIVST or finger prick testing time as 
a proportion of total direct time as an allocating factor. 
Observations were done continuously by health econo-
mists who were trained on time- and- motion studies.
We further explored potential economies of scale by 
observing the incremental unit costs at facility- level as 
number of kits distributed increased. Economies of scale 
are efficiency gains from the increased scale of produc-
tion achieved by spreading fixed costs over more units 
of output. Given the cross- sectional nature of this study, 
we could not observe economies of scale over time for 
each facility but overall relationship between unit costs 
and distribution scale within country
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Finally, a one- way sensitivity analysis was used to assess 
uncertainty around the cost estimates. We varied the 
discount rate from 0% to 15%, project life years from 
1 to 3 years, counsellors' time on HIVST by ±50% and 
personnel costs by ±10%. Additionally, we varied all 




A total of 41 720 kits were distributed across 31 facilities 
in the four countries: 24 553 (59%) kits were distributed 
through the primary distribution channel (Zambia and 
Zimbabwe), while 17 167 (41%) were distributed through 
the secondary distribution channel. In the Malawi trial, 
1603 and 1903 were distributed through the HIVST- only 
and HIVST+FI arms, respectively (table 3).
Time-and-motion studies
We conducted a total of 39 time- and- motion obser-
vations across Malawi (n=9), South Africa (n=28) and 
Zimbabwe (n=2); we interviewed 25 counsellors in 
Zambia. Across all four countries, only the counsellors 
working in the HTS section were involved in HIVST 
distribution. In South Africa, we conducted 19 obser-
vations for 3 hours each during the 3 hours of observa-
tion protocol phase and 9 observations for an average 
of 4 hours per observation during the longer observa-
tion protocol phase. We further observed an average of 
7 hours per counsellor in Malawi, and the two observa-
tions in Zimbabwe were for approximately 5 hours each. 
There is a likely bias in the Malawi and Zimbabwe obser-
vations due to the small sample sizes; we have accounted 
for this by varying the counsellor’s time in the sensitivity 
analysis.
On average, a counsellor spent 32 min in South Africa 
to distribute a kit as presented in table 4. We could not 
perform a per kit analysis in Malawi and Zimbabwe 
due to potential small sample size bias. Overall, the 
counsellors spent an average of 20% and 44% of the 
observed time on HIVST activities in Malawi and 
South Africa, respectively. In the two observations in 
Zimbabwe, the counsellor spent an average of 68% of 
the observed time on HIVST. There was no clear varia-
tion across activities between the countries. Aside from 
HIVST, the counsellors spent a significant proportion 
of the observed time on finger prick testing and non- 
direct patient activities. The interviewed counsellors in 
Zambia reported spending an average of 21% of their 
workday on HIVST.








Malawi: HIV self- testing- 
only arm
– 1603




South Africa – 9282
Zambia 23 416 4262
Zimbabwe 1137 117
Total 24 553 17 167
Table 2 Time- and- motion activity codes
Category Activity Activity description
Direct patient services HIV testing services HIV finger prick testing including pretest and post- test 
counselling.
HIV self- test information Information about self- testing before/without distribution; 
code also used if client declined to take test kit.
HIV testing information Information abount finger prick testing.
Primary HIV self- test distribution HIV self- testing kit primary distribution.
Secondary HIV self- test distribution HIV self- testing kit secondary distribution includes pretest 
counselling and demonstration on how to self- test.
HIV testing with secondary distribution HIV testing services that included a secondary distribution of 
HIV self- testing.
Other direct patient services Time allocated to services that are not related to HIV testing 
and HIV self- testing such as provision of family planning 
methods and antiretroviral treatment initiation.
HIV self- test administration Predrive administration such as paperwork.
HIV testing administration Pretesting administration such as paperwork.
Non- direct patient 
services
Driving to site Driving time for the distributor/counsellor to reach the site 
from the implementers’ office.
Non- direct patient services Any time spent not facing clients such as lunch breaks and 
waiting for clients.
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Costs
The costs per kit distributed through the primary distri-
bution channel were $4.27 in Zambia and $9.24 in 
Zimbabwe. The costs per kit distributed through the 
secondary distribution channels were $6.46 in Zambia, 
$8.66 in Malawi, $9.05 in Zimbabwe and $13.42 in South 
Africa. Table 5 provides a summary of the total costs of 
distributing HIVST kits across all facilities by country.
Personnel and test kit costs were the key cost drivers 
across all four countries (figure 1). Personnel costs 
ranged from 12% of total costs in Zambia’s primary distri-
bution channel to 64% in South Africa. The hourly wage 
per counsellor was $1.10 in Malawi, $2.99 in Zambia, 
$3.32, $4.16 in Zimbabwe and $4.25 in South Africa. 
Test kit costs ranged from 17% of total costs in South 
Africa to 63% in Zambia’s primary distribution channel. 
Additionally, Malawi had relatively higher training costs 
accounting for 18% of total costs with the rest of the 
countries’ training costs ranging from 1% in South Africa 
to 8% in Zimbabwe. We could not completely ascertain 
Table 4 Average observed time per kit distributed in South Africa
Time category
Average time in minutes/kits distributed
3 hours observations (n=19) >3 hours observations (n=9) Combined protocols (n=28)
Direct HIV self- testing time 5.58 17.63 11.60
Indirect HIV self- testing time 9.39 31.20 20.30
Total HIV self- testing time (% of 
total counsellors’ time)
14.96 (34%) 48.83 (65%) 31.90 (44%)
Total kits distributed during 
observations
78 27 105
HIVST, HIV self- testing.
Table 5 Total costs of HIV self- test kit distribution by country (2019 US$)
Country Zambia Zimbabwe Malawi South Africa
Distribution
  Primary Secondary Primary Secondary Secondary
Capital costs
  Training $3435 $1118 $807 $83 $5584 $1049
  Sensitisation $653 $119 $211 $22 $583 $740
  Building and storage $1441 $2771 $191 $17 $233 $886
  Equipment $2225 $1311 $77 $8 $136 $1827
  Other start- up costs – – – – – $161
Recurrent costs
  Personnel $11 685 $6596 $4216 $398 $8511 $79 837
  Supplies $3472 $167 $714 $74 $891 $9236
  Test kits $63 223 $11 507 $2672 $275 $8975 $20 792
  Transport $1772 $323 $637 $66 $2352 $244
  Recurrent training $4044 $1600 – – – –
  Building operation and 
maintenance
$3023 $1107 $272 $27 $3009 $7292
  Waste management $1052 $169 $30 $19 – –
  mHealth – – – – – $2492
  Other recurrent $3929 $756 $681 $70 $105 –
Total $99 954 $27 544 $10 508 $1059 $30 379 $124 556
Total kits distributed 23 416 4262 1137 117 3506 9282
Facilities/country* 3 3 2 2 18 8
Average kits distributed/facility 7805 1421 569 59 195 1060
Cost/kit $4.27 $6.46 $9.24 $9.05 $8.66 $13.42
Facility- level cost/kit (min–
max)
$4.17–$35.64 N/A $4.67–$17.40 $4.59–$132.00
*Primary and secondary distribution in Zambia and Zimbabwe was done in the same clinics; therefore, our analysis was conducted in a total of 31 
clinics even though we have 36 observations.
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why Malawi had higher training costs, though the most 
plausible explanation would be its unique implementa-
tion approach through a clinical trial. The South Africa 
implementation included a component of mHealth for 
linking clients screening positive to follow- on care.22 
The unit cost for the mHealth intervention was $0.27, 
accounting for 2% of total costs.
 
The country- level average costs conceal a wide varia-
tion in average costs by facility, especially in South Africa 
(figure 2). The facility- level average costs in South Africa 
ranged from $4.59 in a facility that distributed 2182 kits 
to $132 in a facility that distributed 103 kits. The facilities 
with the lowest average costs in South Africa were rural 
with low distribution volumes implying potential econo-
mies of scale to HIVST implementation. This facility- level 
cost analysis allowed us to explore other potential econ-
omies of scale across the 36 observations included in this 
analysis, as presented in figure 2. We observed potential 
economies of scale in Malawi and South Africa, that is, 
lower average costs in facilities that distributed a higher 
number of kits, but not Zambia and Zimbabwe.
Sensitivity analysis
Figure 3 presents the sensitivity analysis results where we 
varied the discount rate, project life years, counsellors’ 
time allocated to HIVST and personnel costs. In Malawi, 
the average cost was most sensitive to project life years, 
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Figure 2 Economies of scale by facility and country. We grouped countries by ranges of kit volumes, note that the graphs are 
not using the same scale. For ease of presentation, we excluded one facility in South Africa with kit volume of 103 and average 
cost $132 and one facility in Zambia with kit volume 13 104 and unit cost $3.78
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were assumed to have a lifespan of 1 year. In South Africa 
and Zimbabwe, the average cost was more sensitive to 
personnel costs, and in Zambia, the average cost was more 
sensitive to the providers’ reported time spent on HIVST. 
In Zambia, for instance, doubling the time spent on 
HIVST led to a 11% rise in average costs, compared with 
approximately 5% rise in South Africa and Zimbabwe. 
Across Malawi and South Africa, the average costs were 
least sensitive to changes in the discount rate.
DISCUSSION
We observed the costs of adding HIVST to existing 
testing services in public facilities. In Malawi, South 
Africa, Zambia and Zimbabwe, HIVST was distributed 
through primary and secondary distribution approaches 
using unincentivised HIV testing counsellors. Costs per 
kit distributed were comparable across the countries. 
However, there was a wide variation in the average costs 
at the facility- level, driven mainly by the variability of costs 
in South Africa with the costs at the facility- level varying 
between $4.59 and $132. This study fills a gap in literature 
by reporting multicountry costs of integrating HIVST 
in public facilities, which is a viable option as countries 
approach the last milestone of the UNAIDS first 95.
In Zambia and Zimbabwe, the average costs of the 
integrated distribution observed in this study were lower 
than the inflation adjusted average costs of community- 
based distribution of HIVST reported in our earlier 
work.13 The average costs of community- based distribu-
tion in Zimbabwe and Zambia were 1.6 and three times 
higher than facility incremental costs ($14.69 vs $9.14 in 
Zimbabwe and $17.00 vs $5.37 in Zambia), respectively. 
This is expected as the community- based distribution was 
a vertical intervention unlike the integrated facility distri-
bution that leveraged on existing economies of scope 
through shared infrastructure and human resource. It 
is worth noting that integration of HIV testing services 
may not always lead to efficiency gains in service delivery 
as observed elsewhere23 and in the Malawi component 
of this study where the average costs of the facility and 
community- based distribution in Malawi were compa-
rable, that is, $8.66 versus $8.58, respectively.
Furthermore, despite the time- and- motion study 
raising generalisability concerns due to majority of the 
observations coming from South Africa, the results still 
offer insight into time demanded by HIVST from the 
counsellors. Counsellors spent at least 20% and 44% 
of the observed workday on direct and indirect HIVST 
activities in Malawi and South Africa. These results are 
informative to the time burden on the counsellors intro-
duced by HIVST and have implications for the sustain-
ability of HIVST scale- up. The degree of integration and 
the counsellors’ perception of HIVST are important 
factors in ensuring sustainability. HIVST needs to be 
horizontally integrated to ensure that the counsellors 
perceive it as a part of their routine. A viable alternative 
is unassisted primary distribution of HIVST, which has 
the potential of reducing staff time commitment espe-
cially for heavily understaffed facilities and improving 
linkage to follow on treatment or prevention services. 
For secondary distribution, pooled demonstration 
through for example videos streamed in the waiting 
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Figure 3 Sensitivity and scenario analysis by country. Note that the tornado diagrams are not drawn to the same scale. Base 
case in Zambia and Zimbabwe combines primary and secondary distribution unit costs.
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Additionally, the cost driver analysis demonstrated the 
importance of personnel and test kits in driving the inte-
gration costs. Our previous studies on facility- based HIV 
testing and community- based HIVST distribution also 
reported the costs of test kits and personnel as key cost 
drivers.13 20 The significance of personnel costs as a crit-
ical cost driver cannot be understated, as demonstrated 
by the time- and- motion studies. There is an opportunity 
cost to counsellors’ time—an intervention such as HIVST 
may be taking away time from the provision of other 
essential healthcare interventions especially in facilities 
that do not use lay counsellors for HIVST distribution. It 
is also important to ensure that HIVST is not introduced 
in facilities as a replacement for finger- prick testing but 
as an alternative testing option with the aim of expanding 
choice and supporting any potential efficiency gains.8
There are potential economies of scale to HIVST 
implementation. Average costs were lower in sites with 
high number of kits distributed due to shared fixed/
overhead costs, and outlier facilities in South Africa were 
rural with low number of HIVST kits distributed. The 
average costs for such facilities need to be evaluated not 
relative to the high- volume facilities with low average cost 
but the counterfactual for such rural areas, no testing for 
the populations left behind.
Finally, this study has the advantage of being a multi-
country costing study on integrating HIVST to existing 
testing services in 31 public facilities. This gives us a better 
understanding of the feasibility and cost implications of 
such an approach across countries. The time- and- motion 
studies enabled us to understand the time commitments 
required by unincentivised counsellors in an integrated 
approach of delivering HIVST in public health facilities. 
We propose room for efficiency gains at the facility- level, 
as demonstrated by the heterogeneity in facility- level 
costs24; this could be further explored using data envel-
opment analysis.25 We also recommend demand creation 
activities and continued kit price negotiations to ensure 
the intervention’s sustainability and continued afford-
ability, especially at scale- up.
Limitations
There are several limitations to this study. A central limi-
tation is that a substantial sample (58%) of the cost facili-
ties was based on a trial. Despite excluding research costs, 
there may be higher protocol- induced resource use costs, 
and uptake, which may not be observed at scale- up.
There is also a likely upward bias in the observed time 
counsellors spent on HIVST due to Hawthorne effect, 
whereby individuals change their behaviour under obser-
vation.26 If the counsellors expected a financial incentive 
from HIVST integration, there was potential for them 
to spend more time on HIVST distribution during the 
observations. Nonetheless, we deem it advantageous to 
collect the time- and- motion data rather than basing the 
estimation of personnel resource costs solely on retro-
spective interviews, which is subject to the same bias but 
with the added challenge of recall bias.
An additional limitation is our inability to construct 
an index of integration to assess the complex nature of 
integration at the facility- level and to understand the 
sources of heterogeneity in facility- level cost due to lack 
of data.9 27
Finally, constructing cost functions would have been 
more informative in exploring potential sources of cost 
heterogeneity at the facility- level. We had few facilities 
within the countries with even more limited variables 
collected per facility to fully parameterise a cost func-
tion analysis. However, aside from South Africa, the rest 
of the countries’ average costs were more homogenous, 
suggesting potential uniformity in integrated service 
delivery.
CONCLUSION
We conducted a cost analysis of an intervention that 
integrated HIVST into existing HIV testing services in 
public facilities in Malawi, South Africa, Zambia and 
Zimbabwe. The average cost of integrating HIVST into 
public facilities ranged from $4.27 to $13.42 per kit 
distributed between countries. Personnel and cost of test 
kits were the critical cost drivers. We recommend taking 
the context into account when integrating HIVST into 
existing testing services. Finally, where staff time may be a 
constraint for conventional testing, HIVST may help alle-
viate this by enabling clients to have unassisted testing.
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